RHON-KLINIKUM AG closed the first nine months of 2026 with strong earnings growth, reporting an 8.3% increase in patients treated and a rise in consolidated profit to EUR 32.7 million, up from EUR 25.1 million in the prior-year period. The results, announced via NEWMEDIAWIRE, underscore the group's ability to navigate healthcare policy challenges and a difficult economic environment while continuing to invest in state-of-the-art medical technology.
From January to September 2026, RHON-KLINIKUM treated 764,248 patients on an inpatient and outpatient basis, up from 705,830 in the same period of 2025. Consolidated revenue rose to EUR 1,303.8 million from EUR 1,262.1 million, and EBITDA increased to EUR 83.9 million from EUR 71.8 million. The operating result was boosted by a 3.25% billing surcharge on hospital services, accounted for under "other income" through October 2026, intended to offset rises in personnel and non-personnel costs. The increase in consolidated profit was primarily driven by higher capacity utilization at clinics and medical care centers, particularly in the outpatient sector.
The company's strong capital base, reflected in an equity ratio of 74.7%, provides a solid foundation for optimizing inpatient and outpatient care structures. Dr. Gunther K. WeiB, member of the Board of Management, stated: "Our successful third quarter shows that financial stability and medical excellence are inseparable, going hand in hand. Underlying this success is the tremendous trust our patients put in us. This sustainable basis is what allows us to continue making targeted investments in state-of-the-art medical technology and care offerings."
These investments include a state-of-the-art photon-counting computer tomograph at Universitatsklinikum Marburg, making RHON-KLINIKUM the only hospital group in Germany with four newest-generation units in operation. Additionally, a new hybrid operating theatre in Frankfurt (Oder) has expanded the hospital's treatment range and strengthened interdisciplinary structures in the Ostbrandenburg region. Dr. Stefan Stranz, member of the Board of Management, noted: "This forward-looking investment strategy ensures that we can continue to operate effectively in a market environment facing far-reaching and sweeping change. Thanks to our solid financial basis and our collaboration within the ASKLEPIOS Group network, we can take on and actively shape this transformation process from a position of strength."
For the full year 2026, RHON-KLINIKUM expects revenues of EUR 1.7 billion within a range of plus or minus 5%, and EBITDA between EUR 110 million and EUR 125 million. However, the financial year will be significantly impacted by the unfolding legislation process, particularly the Hospital Reform Adjustment Act (KHAG) that entered into force on 15 April 2026 and the Statutory Health Insurance Contribution Rate Stabilisation Act (GKV-BStabG) adopted on 10 July 2026. While these laws aim to enhance quality and efficiency, they will put hospitals under greater financial pressure in the short term. The company's forecast is therefore subject to particular uncertainties, and it is not yet possible to reliably forecast the overall impact of ongoing regulatory interference, hospital reform implementation, and further possible adjustments, as well as ongoing global crises and negative economic impacts that result in higher prices, supply bottlenecks, and market volatility.
The Quarterly Statement for Q3 2026 is available on the Internet. RHON-KLINIKUM AG, a company of the ASKLEPIOS Group, operates five highly specialized maximum- and intermediate-care facilities and employs over 19,100 people, treating 938,000 patients annually. Further information is available at www.rhoen-klinikum-ag.com.


